200 related articles for article (PubMed ID: 33737193)
1. Sclerostin antibody increases trabecular bone and bone mechanical properties by increasing osteoblast activity damaged by whole-body irradiation in mice.
Costa S; Fairfield H; Farrell M; Murphy CS; Soucy A; Vary C; Holdsworth G; Reagan MR
Bone; 2021 Jun; 147():115918. PubMed ID: 33737193
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin-Neutralizing Antibody Treatment Rescues Negative Effects of Rosiglitazone on Mouse Bone Parameters.
Farrell M; Fairfield H; Costa S; D'Amico A; Falank C; Brooks DJ; Reagan MR
J Bone Miner Res; 2021 Jan; 36(1):158-169. PubMed ID: 32845528
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
Cardinal M; Dessain A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
Calcif Tissue Int; 2020 May; 106(5):494-508. PubMed ID: 32025752
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms.
Chandra A; Lin T; Young T; Tong W; Ma X; Tseng WJ; Kramer I; Kneissel M; Levine MA; Zhang Y; Cengel K; Liu XS; Qin L
J Bone Miner Res; 2017 Feb; 32(2):360-372. PubMed ID: 27635523
[TBL] [Abstract][Full Text] [Related]
5. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
Ominsky MS; Brown DL; Van G; Cordover D; Pacheco E; Frazier E; Cherepow L; Higgins-Garn M; Aguirre JI; Wronski TJ; Stolina M; Zhou L; Pyrah I; Boyce RW
Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
[TBL] [Abstract][Full Text] [Related]
6. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.
Yao W; Dai W; Jiang L; Lay EY; Zhong Z; Ritchie RO; Li X; Ke H; Lane NE
Osteoporos Int; 2016 Jan; 27(1):283-294. PubMed ID: 26384674
[TBL] [Abstract][Full Text] [Related]
8. Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume.
Morse A; Cheng TL; Schindeler A; McDonald MM; Mohanty ST; Kneissel M; Kramer I; Little DG
Calcif Tissue Int; 2018 Sep; 103(3):298-310. PubMed ID: 29845410
[TBL] [Abstract][Full Text] [Related]
9. Inverse correlation between trabecular bone volume and bone marrow adipose tissue in rats treated with osteoanabolic agents.
Costa S; Fairfield H; Reagan MR
Bone; 2019 Jun; 123():211-223. PubMed ID: 30954729
[TBL] [Abstract][Full Text] [Related]
10. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia.
Achiou Z; Toumi H; Touvier J; Boudenot A; Uzbekov R; Ominsky MS; Pallu S; Lespessailles E
Bone; 2015 Dec; 81():691-701. PubMed ID: 26409255
[TBL] [Abstract][Full Text] [Related]
11. Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss.
Beggs LA; Ye F; Ghosh P; Beck DT; Conover CF; Balaez A; Miller JR; Phillips EG; Zheng N; Williams AA; Aguirre JI; Wronski TJ; Bose PK; Borst SE; Yarrow JF
J Bone Miner Res; 2015 Apr; 30(4):681-9. PubMed ID: 25359699
[TBL] [Abstract][Full Text] [Related]
12. Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.
Grafe I; Alexander S; Yang T; Lietman C; Homan EP; Munivez E; Chen Y; Jiang MM; Bertin T; Dawson B; Asuncion F; Ke HZ; Ominsky MS; Lee B
J Bone Miner Res; 2016 May; 31(5):1030-40. PubMed ID: 26716893
[TBL] [Abstract][Full Text] [Related]
13. Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse.
Cardinal M; Chretien A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Manicourt DH; Behets C
Front Genet; 2021; 12():705505. PubMed ID: 34447412
[TBL] [Abstract][Full Text] [Related]
14. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
[TBL] [Abstract][Full Text] [Related]
15. Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations.
Willey JS; Livingston EW; Robbins ME; Bourland JD; Tirado-Lee L; Smith-Sielicki H; Bateman TA
Bone; 2010 Jan; 46(1):101-11. PubMed ID: 19747571
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin antibody promotes bone formation through the Wnt/β-catenin signaling pathway in femoral trochlear after patellar instability.
Xu C; Ji G; Chen X; Yan L; Liang T; Liu J; Wang F
Connect Tissue Res; 2023 Mar; 64(2):148-160. PubMed ID: 36379907
[TBL] [Abstract][Full Text] [Related]
17. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody.
Ominsky MS; Niu QT; Li C; Li X; Ke HZ
J Bone Miner Res; 2014 Jun; 29(6):1424-30. PubMed ID: 24967455
[TBL] [Abstract][Full Text] [Related]
18. The effects of sclerostin antibody plus parathyroid hormone (1-34) on bone formation in ovariectomized rats.
Wu J; Cai XH; Qin XX; Liu YX
Z Gerontol Geriatr; 2018 Jul; 51(5):550-556. PubMed ID: 28364259
[TBL] [Abstract][Full Text] [Related]
19. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
Sun W; Shi Y; Lee WC; Lee SY; Long F
Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.
Tian X; Jee WS; Li X; Paszty C; Ke HZ
Bone; 2011 Feb; 48(2):197-201. PubMed ID: 20850580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
